Skip to Main Content
+
Cannon  CP, Braunwald  E, McCabe  CH,  et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495–1504. doi:10.1056/NEJMoa040583 
+
Colhoun  HM, Betteridge  DJ, Durrington  PN,  et al; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomized placebo-controlled trial. Lancet. 2004;364(9435):685–696. doi:10.1016/S0140-6736(04)16895-5 
+
deLemos  JA, Blazing  MA, Wiviott  SD,  et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA.[JAMA and JAMA Network Journals Full Text] 2004;292:1307–1316. doi:10.1001/jama.292.11.1307 
+
Downs  JR, Clearfield  M, Weis  S,  et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA.[JAMA and JAMA Network Journals Full Text] 1998:279(20):1615–1622. doi:10.1001/jama.279.20.1615 
+
Fellstrom  BC, Jardine  AG, Schmeider  RE,  et al; AURORA study group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14);1395–1407. doi:10.1056/NEJMoa0810177 
+
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20356 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.  [PubMed: 12114036]
+
LaRosa  JC, Grundy  SM, Waters  DD,  et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–1435. doi:10.1056/NEJMoa050461 
+
Ridker  PM, Danielson  E, Fonseca  FA,  et al; JUPITER study group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21);2195–2207. doi:10.1056/NEJMoa0807646 
+
Sacks  FM, Pfeffer  MA, Moye  LA,  et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335(14):1001–1009. doi:10.1056/NEJM199610033351401 
+
Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389.  [PubMed: 7968073]
+
Schwartz  GG, Olsson  AG, Ezekowitz  MD,  et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL Study: a randomized controlled trial. JAMA.[JAMA and JAMA Network Journals Full Text] 2001;285:1711–1718.  [PubMed: 11277825]
+
Sever  PS, Dahlof  B, Poulter  NR,  et al; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicenter randomized controlled trial. Lancet. 2003;361(9364):1149–1158. doi:10.1016/S0140-6736(03)12948-0 
+
SHARP Collaborative group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9438 patients with chronic kidney disease. Am Heart J. 2010;160(5):785–794. doi:10.1016/j.ahk.2010.08.012 
+
Shepherd  J, Blauw  GJ, Murphy  MB,  et al; PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet. 2002;360(9346):1623–1630. doi:10.1016/s0140-6736(02)11600-x 
+
Shepherd  J, Cobbe  SM, Ford ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.